Valuation: Devyser Diagnostics AB

Market Cap 912M 91.41M 81.15M 75.94M 68.83M 130M 8.81B 131M 355M 4.5B 343M 336M 14.45B P/E 2026 *
88.9x
P/E 2027 * 27.9x
Enterprise Value 865M 86.7M 76.96M 72.02M 65.28M 123M 8.36B 124M 336M 4.26B 325M 318M 13.71B EV / Sales 2026 *
3.52x
EV / Sales 2027 * 2.93x
Free-Float
70.78%
Yield 2026 *
-
Yield 2027 * -
1 day+1.16%
1 week+7.05%
Current month+8.14%
1 month-10.56%
3 months-35.86%
6 months-32.32%
Current year-53.18%
1 week 4.42
Extreme 4.415
4.82
1 month 4.38
Extreme 4.385
5.36
Current year 4.38
Extreme 4.385
10.56
1 year 4.38
Extreme 4.385
12.72
3 years 4.38
Extreme 4.385
14.2
5 years 4.38
Extreme 4.385
14.2
10 years 4.38
Extreme 4.385
14.2
Manager TitleAgeSince
Chief Executive Officer 59 04/08/2025
Director of Finance/CFO 43 01/01/2021
Chief Tech/Sci/R&D Officer 48 01/02/2024
Director TitleAgeSince
Chairman 57 27/05/2021
Director/Board Member 49 01/01/2021
Director/Board Member 72 01/01/2021
Change 5-day change 1-year change 3-year change Capi.($)
+1.16%+7.05% - - 90.82M
+4.16%+3.42%+49.37%+94.17% 74.31B
+2.76%-1.16%+23.05%+83.03% 56.95B
+0.24%-1.37%+4.08%+37.22% 48.3B
-3.76%-2.25%+329.09%+698.20% 44.51B
-2.30%-3.35%+26.81%+30.88% 43.8B
+0.31%-0.68%+5.30%+108.64% 41.12B
-0.11%+2.30%+9.19%+58.68% 31.07B
+4.51%+8.43%+37.27%+34.97% 28.97B
-1.96%-2.88%-8.97%-13.92% 24.53B
Average +0.50%-0.20%+52.80%+125.76% 43.73B
Weighted average by Cap. +0.77%-0.50%+56.83%+134.46%

Financials

2026 *2027 *
Net sales 246M 24.65M 21.88M 20.48M 18.56M 35.05M 2.38B 35.31M 95.66M 1.21B 92.53M 90.54M 3.9B 298M 29.82M 26.48M 24.78M 22.46M 42.41M 2.88B 42.72M 116M 1.47B 112M 110M 4.72B
Net income 10.07M 1.01M 896K 838K 760K 1.43M 97.26M 1.45M 3.92M 49.61M 3.79M 3.71M 159M 31.97M 3.2M 2.84M 2.66M 2.41M 4.56M 309M 4.59M 12.44M 158M 12.03M 11.77M 507M
Net Debt -47.04M -4.71M -4.19M -3.92M -3.55M -6.7M -455M -6.75M -18.3M -232M -17.7M -17.32M -745M -39M -3.91M -3.47M -3.25M -2.94M -5.56M -377M -5.6M -15.17M -192M -14.67M -14.36M -618M
Projected Income Statement - Annual - Devyser Diagnostics AB
Logo Devyser Diagnostics AB
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnostics’ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
Employees
110
Date Price Change
07/10/26 EUR 4.785 +1.16%
05/10/26 EUR 4.730 -1.15%
02/10/26 EUR 4.785 +6.22%
01/10/26 EUR 4.505 +1.81%
30/09/26 EUR 4.425 -0.23%
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - Devyser Diagnostics AB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
35.84DKK
Average target price
65.94DKK
Spread / Average Target
+83.98%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Devyser Diagnostics AB